Cadence Capital Management LLC reduced its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 41.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,323 shares of the medical instruments supplier’s stock after selling 51,781 shares during the quarter. Cadence Capital Management LLC owned 0.12% of OraSure Technologies worth $1,650,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in OSUR. Daruma Capital Management LLC raised its holdings in shares of OraSure Technologies by 2,761.0% in the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after acquiring an additional 2,722,886 shares in the last quarter. Vanguard Group Inc. grew its stake in OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after purchasing an additional 1,037,439 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in OraSure Technologies by 175.6% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock valued at $20,214,000 after purchasing an additional 572,397 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its stake in OraSure Technologies by 2,181.8% in the third quarter. Robeco Institutional Asset Management B.V. now owns 434,550 shares of the medical instruments supplier’s stock valued at $9,778,000 after purchasing an additional 415,506 shares during the last quarter. Finally, SG Capital Management LLC purchased a new position in OraSure Technologies in the third quarter valued at about $9,205,000. Hedge funds and other institutional investors own 94.51% of the company’s stock.

In other news, CEO Douglas A. Michels sold 25,000 shares of the business’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $22.55, for a total transaction of $563,750.00. Following the sale, the chief executive officer now owns 743,058 shares in the company, valued at $16,755,957.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

OSUR has been the topic of several analyst reports. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Saturday, September 9th. Jefferies Group reiterated a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 12th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 19th. Finally, ValuEngine lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $18.21.

OraSure Technologies, Inc. (NASDAQ:OSUR) opened at $17.03 on Friday. OraSure Technologies, Inc. has a 52 week low of $8.21 and a 52 week high of $23.01. The stock has a market capitalization of $1,030.00, a PE ratio of 31.83, a price-to-earnings-growth ratio of 3.18 and a beta of 1.39.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The company had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. analysts expect that OraSure Technologies, Inc. will post 0.42 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/02/cadence-capital-management-llc-sells-51781-shares-of-orasure-technologies-inc-osur.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.